Healthcare Equipment and Supplies
Company Overview of T2 Biosystems, Inc.
T2 Biosystems, Inc. develops direct detection products for diagnostic applications. It offers T2Dx System, a diagnostic product that consists of a benchtop instrument and a disposable cartridge that is pre-loaded with nanoparticle reagents; and T2MR platform, a magnetic biosensor detector for detection of infectious diseases. The company also provides T2Candida assay, which is designed to provide life and cost-saving benefits to patients and hospitals through direct detection and multiplexed analysis of species of the fungal pathogen Candida; and T2Hemostasis, a platform for characterizing key coagulation, platelet, and other hematologic factors directly from whole blood. Its products detect...
101 Hartwell Avenue
Lexington, MA 02421
Founded in 2006
Key Executives for T2 Biosystems, Inc.
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2013.
T2 Biosystems, Inc. Key Developments
T2 Biosystems to Exhibit Sepsis and Hematology Panels Based on Breakthrough T2MR(R) Direct Detection Technology at the Association for Molecular Pathology Annual Meeting
Nov 11 13
T2 Biosystems announced that it will provide demonstrations of its sepsis and hemostasis diagnostic platforms based on the company's T2MR(R) direct detection technology at Booth #431 at the Association for Molecular Pathology 2013 Annual Meeting, November 14-16, 2013, in Phoenix, AZ. T2MR is a breakthrough detection technology that enables rapid and sensitive analysis of virtually any diagnostic target by enabling direct detection in clinical samples, such as whole blood, without the need for sample preparation. T2 Bio's test panel, T2Candida(R), directly detects five species of sepsis-causing Candida in a whole blood specimen in approximately 3 hours with a limit of detection as low as 1 CFU/mL without the need for blood culture. The T2Candida test is currently in a pivotal clinical trial, and results will be available in the first half of 2014. T2HemoStat(TM) enables rapid characterization of key hematologic factors, such as platelet function testing, clotting times, anti-platelet therapeutic monitoring and novel hemostasis biomarkers for prothrombotic states, bleeding, fibrinolysis and clot structures, directly from small volumes (5-40uL) of whole blood. The T2Candida assay is run on the T2Dx(R) instrument and the T2HemoStat test is run on the compact T2Stat(TM) instrument, both of which utilize the Company's T2MR technology. T2MR uses miniaturized magnetic resonance to directly detect virtually any immunodiagnostic, molecular or hemostasis target from complex clinical samples, such as whole blood, plasma, serum, sputum and urine. The T2Candida test and T2Dx instrument are currently intended for Investigational Use Only. The performance characteristics of these products have not yet been established. The T2HemoStat test and T2Stat instrument are currently intended for Research Use Only. They are not presently intended for use in diagnostic procedures.
T2 Biosystems Expands Intellectual Property Portfolio Covering T2MR(R) Direct Detection Diagnostic Platform
Oct 22 13
T2 Biosystems, announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the protection of the Company's T2MR(R) platform and the T2Dx(R) detection system. Both patents are part of the growing intellectual property estate protecting T2 Bio's breakthrough detection capabilities, including the company's T2Candida(R) multiplex test panel that detects the presence of species-specific Candida directly from whole blood in approximately three hours without the requirement for blood culturing. The patents describe a sample containing nanoparticles for use in detecting analytes in whole blood samples and the inlet module of the insertable cartridge for use with the T2Dx instrument. US Patent 8,563,298 describes the composition of an analyte and magnetic nanoparticles with specific size and relaxation properties and the ability to specifically bind to an analyte. This patented composition is core and unique to the T2Dx platform assays that use T2MR, a proprietary magnetic resonance detection system, and the claims are protective of the T2Candida assay as well as future assays. Patent USD 691,733, Modular cartridge assembly, is a follow-on design patent to a previously issued patent protecting the features of the insertable cartridge to dispense a blood sample for use in the T2Candida or other whole blood assay on the T2Dx instrument. T2 Biosystems patent portfolio consists of 29 issues patents worldwide.
T2 Biosystems to Exhibit Rapid and Sensitive Assay for Sepsis Pathogens at IDWeek 2013
Sep 30 13
T2 Biosystems announced that it will provide demonstrations of its flagship test, T2Candida(R), for the rapid and sensitive identification of species-specific Candida directly from whole blood, on its T2Dx(R) instrument at Booth #922 at IDWeek 2013, October 2-6, 2013, in San Francisco, CA. Without the need for blood culture, T2Candida directly detects five species of Candida in a whole blood specimen in approximately 3 hours with a limit of detection as low as 1 CFU/mL. The T2Candida test is currently being evaluated in a pivotal clinical trial, and results will be available in the first half of 2014. T2Candida has the potential to address a significant health threat as described in the recently published report on Antimicrobial Resistant Threats in the United States, 2013 by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention, which places Candida in the Serious Hazard Level category. As a Serious Threat, the CDC warns that ongoing monitoring and prevention is necessary to prevent Candida from becoming an Urgent Hazard. The T2Candida assay is run on the T2Dx instrument, which utilizes the Company's T2MR(R) technology. T2MR uses miniaturized magnetic resonance to directly detect any immunodiagnostic, molecular or hemostasis target from complex clinical samples, such as whole blood, plasma, serum, sputum and urine.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 22, 2013